The following information is disclosed in accordance with Rule 26 of the AIM Rules (July 2016). These requirements were last reviewed and updated by the company on 4th January 2021.
| Description of Business | Redx Pharma was formed in 2010 and is an established drug discovery and development company based at Alderley Park. The Group’s work has been endorsed by partnerships with global pharmaceutical companies, and focuses on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need in cancer and fibrosis. | ||||||
| Incorporation & Registered Office | Redx Pharma Plc is registered in England & Wales number 07368089, Block 33, Mereside, Alderley Park, Alderley Edge, Macclesfield SK10 4TG |
||||||
| Directors | Iain Ross (Chairman) Lisa Anson (CEO) Peter Presland (Non-Executive Director, Chairman of Audit & Disclosure Committee) Dr Bernard Kirschbaum (Non-Executive Director) Dr James Mead (CFO) Sarah Gordon Wild (Non-Executive Director) Dr Thomas Burt (Non-Executive Director) View Directors’ biographies |
||||||
| Advisors | Nominated Advisor SPARK Advisory Partners Limited 5 St. John’s Lane, London, EC1M 4BH, UK Broker WG Partners LLP 85 Gresham Street London EC2V 7NQ, UK Auditor RSM UK Audit LLP 3 Hardman Street Manchester M3 3HF, UK Financial Communications Advisor FTI Consulting 200 Aldersgate Street London EC1A 4HD, UK | Legal Advisors Covington and Burling LLP 265 Strand London WC2R 1BH, UK Registrar Equiniti Limited Aspect House Spencer Road Lancing West Sussex BN99 6DA, UK |
|||||
| Corporate Governance | The Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework. The main features of the Group’s corporate governance arrangements are:
| Audit, Risk and Disclosure Committee Peter Presland (C), Bernhard Kirschbaum and Sarah Gordon Wild Remuneration Committee Bernhard Kirschbaum (C), Peter Presland and Sarah Gordon Wild |
|||||
| Constitutional Documents | Articles of Association PDF | ||||||
| Exchanges & Trading Platforms | The Company is not listed on any other Exchanges or Trading Platforms. | ||||||
| Shares & Significant Shareholders | Total number of shares issued: 273,887,213 Number of shares (if any) held in treasury: Nil Shareholders with >3% of total issued: |
||||||
| Name | Number of shares | Percentage of issued shares | |||||
| RM Special Holdings 3 LLP | 217,880,610 | 79.55% | |||||
| Sofinnova Crossover 1 SLP | 25,779,751 | 9.41% | |||||
| Polar Capital | 13,571,429 | 4.96% | |||||
| Last updated 04/01/2021 | |||||||
| Shares Not in Public Hands | Pursuant to the AIM Rules, and insofar as the Company is aware, as at 04/01/2021, 89.48% of the Company’s AIM securities were not in public hands. | ||||||
| Share Restrictions | There are no restrictions on the transfer of securities. | ||||||
| Admission Document | Company admission document PDF | ||||||
| Shareholder Circulars | Click to view Shareholder Circulars | ||||||
| Takeover Code | The Company is subject to the UK City Code on Takeovers and Mergers. | ||||||
| Latest Annual Report | Click to view the latest annual report | ||||||
| RNS Announcements | Click to view the company’s RNS Announcements | ||||||